Payment overview · 2025
General Payments
$1,180.32
91 reported records · 11 companies
Healthcare provider profile · identity verified
Logan Scott Vansickle, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HENDERSON, KY · NPI 1699335968
Verified facts
What the public records show
CMS Open Payments records show Logan Scott Vansickle, APRN received $1,180.32 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 42.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Qulipta, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $506.11 | 42.9% | 47 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $331.56 | 28.1% | 24 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $92.43 | 7.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.65 | 7.4% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.70 | 3.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.86 | 2.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.82 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.71 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.98 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.15 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.35 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,180.32 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $365.83 | 32 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $331.56 | 24 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $269.02 | 24 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $132.32 | 14 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $92.43 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $87.65 | 5 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.86 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 267 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 248 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 40 |
| Lisinopril | Lisinopril | 234 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 38 |
| Furosemide | Furosemide | 156 | 26 |
| Omeprazole | Omeprazole | 151 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 122 | 26 |
| Trazodone Hcl | Trazodone Hcl | 118 | 24 |
| Metformin Hcl | Metformin Hcl | 117 | 28 |
| Alprazolam | Alprazolam | 116 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 111 | 21 |
| Promethazine Hcl | Promethazine Hcl | 102 | 21 |
| Losartan Potassium | Losartan Potassium | 98 | 23 |
| Carvedilol | Carvedilol | 97 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 20 |
| Potassium Chloride | Potassium Chloride | 93 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 18 |
| Meloxicam | Meloxicam | 83 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 19 |
| Clonazepam | Clonazepam | 78 | 15 |
| Bupropion Xl | Bupropion Hcl | 71 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 70 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 15 |
| Mirtazapine | Mirtazapine | 67 | 12 |
| Pregabalin | Pregabalin | 67 | suppressed |
| Diazepam | Diazepam | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 12 |
| Eliquis | Apixaban | 61 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 11 |
| Famotidine | Famotidine | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 14 |
| Sertraline Hcl | Sertraline Hcl | 56 | 12 |
| Buspirone Hcl | Buspirone Hcl | 54 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 50 | 13 |
| Tramadol Hcl | Tramadol Hcl | 50 | 12 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 21 |
| Methocarbamol | Methocarbamol | 47 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 14 |
| Propranolol Hcl | Propranolol Hcl | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | suppressed |
| Prednisone | Prednisone | 41 | 27 |
| Temazepam | Temazepam | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 38 | 12 |
| Risperidone | Risperidone | 38 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 32 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 25 |
| Spironolactone | Spironolactone | 34 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 16 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ubrelvy | Ubrogepant | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 14 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,180.32 · 91 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, FANAPT, HETLIOZ, LEQVIO, NURTEC ODT, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error